Please login to the form below

Not currently logged in
Email:
Password:

Horizon

This page shows the latest Horizon news and features for those working in and with pharma, biotech and healthcare.

Date set for EU antitrust regulators to decide on Pfizer’s $43bn Seagen acquisition

Date set for EU antitrust regulators to decide on Pfizer’s $43bn Seagen acquisition

At the time of the request, concern was rising among investors regarding the FTC’s decision to block Amgen’s proposed $27.8bn takeover of Horizon Therapeutics. ... The Amgen/Horizon transaction has since been allowed to proceed after a proposed

Latest news

More from news
Approximately 24 fully matching, plus 163 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 69 partially matching documents found.

Latest appointments

  • CureVac’s CEO appointed to EC High Level Group CureVac’s CEO appointed to EC High Level Group

    Dr Ingmar Hoerr will advise on Horizon 2020 and future innovation programmes. ... Dr Hoerr joins a panel of 15 group members who will advise the EC on how to strengthen support for breakthrough, market-creating innovation in the Horizon 2020 project as

  • Decibel Therapeutics expands leadership team Decibel Therapeutics expands leadership team

    He co-founded Bright Horizons Family Solutions, a worksite childcare and early education provider, and prior to this served as co-director of Save the Children's Sudan operations.

  • Eric Rhodes becomes CEO of ERS Genomics Eric Rhodes becomes CEO of ERS Genomics

    Rhodes joins ERS Genomics from Horizon Discovery, where he served as senior vice president of research and development and chief technology officer. ... Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of

  • Jane Osbourn to chair BIA board Jane Osbourn to chair BIA board

    The new members of the board are Darrin Disley, chief executive of Horizon Discovery Group and David Hipkiss, chief business officer at Circassia Pharmaceuticals.

  • Adaptimmune appoints Lawrence Alleva to its board Adaptimmune appoints Lawrence Alleva to its board

    He currently serves as a director for public companies Tesaro and Bright Horizons Family Solutions, and for the privately-held Mirna Therapeutics, and chairs those companies' audit committees.

More from appointments
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 44 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....